诺辉健康是中国癌症早筛的引领者和居家检测的开创者，中国首家专注于癌症早筛的生物高科技公司，率先提出“高发癌症居家早期筛查”的服务理念。其自主研发的“非侵入性，多靶点粪便FIT-DNA联合检测”产品--常卫清®是中国首个，且现阶段唯一的肠癌早筛产品。产品管线覆盖肠癌、宫颈癌、胃癌和肺癌等领域。针对中国人高发癌种，诺辉健康致力于提供最适宜的早期筛查解决方案，让用户足不出户即可享受准确高效、便捷的癌症早筛服务。
Location: China, Jiangxi, Binjiang
Employees: 1-10
Total raised: $20M
Founded date: 2013
Investors 6
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | Lake Bleu ... | lakebleu-c... |
| - | Octagon Ca... | octagoninv... |
| - | Qiming Ven... | qimingvent... |
| - | Acorn Paci... | acornpacif... |
| - | Qiming Ven... | qimingvc.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.08.2017 | Series D | $20M | Qiming Ven... |
Mentions in press and media 4
| Date | Title | Description |
| 20.08.2022 | New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82% | HANGZHOU, Aug 19, 2022 - (ACN Newswire) - New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today. Based on the financial informa... |
| 27.05.2019 | China Digest: SoftBank-backed New Horizon Health closes Series C; LyncMed raises $20m | Premium New Horizon Health, a Chinese early-stage cancer screening developer, has secured $66 million in a series C funding round while medical device e-commerce platform LyncMed has raised $20 million in a series B+1 round. Continue readin... |
| 09.08.2017 | China Dealbook: FMC raises $200m; Qiming leads $20m in New Horizon | Premium Chinese electric vehicle maker Future Mobility Corp. (FMC) raised $200 million in a new financing round at $750 million valuation, while Qiming Venture Partners led a $20 million funding round in Chinese healthcare start-up New Hori... |
| - | Chinese Cancer Screening Firm New Horizon Health Raises $20M In Series D Round | - |